HC Wainwright & Co. analyst Mitchell Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and maintains $7 price target.
- Headlines
- HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $7 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
10:57
China Photovoltaic Industry Association: The forecast for global new installations in 2024 has been raised to 430GW-470GW.
10:56
In November, the average temperature in China reached a new high for the same period since 1961.
10:55
Lottem Group: plans to issue $0.55 billion perpetual subordinated bonds. The proceeds from the issuance will mainly be used to redeem or repurchase previously issued bonds.
Rakuten Group-0.70%